Overview

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered to Adults With Multiple System Atrophy

Status:
Active, not recruiting
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of multiple doses of BIIB101 administered via intrathecal (IT) injection to participants with multiple system atrophy (MSA). The secondary objective is to evaluate the pharmacokinetic (PK) profile of BIIB101.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen